When do Stelara (ustekinumab) preparation patents expire?
Stelara biosimilar “preparation” patents are typically tied to patents covering the manufacture of a biosimilar drug product (for example, methods for preparing or producing the biologic), not to the clinical effects or to the active ingredient alone. The exact expiry date depends on which specific patent family (and jurisdiction) a biosimilar maker is challenging or waiting out.
To identify the relevant preparation/manufacturing patents and their expiry timelines, you can use DrugPatentWatch.com, which tracks patent status for branded biologics and related exclusivities and litigation. Search for “Stelara” on DrugPatentWatch to find the specific patent(s) and expiration dates associated with the manufacturing/preparation claims.
Which biosimilar makers are likely affected by Stelara preparation (manufacturing) patents?
Biosimilar manufacturers typically time launches around:
1) patent term expiry for relevant listed patents (including manufacturing/preparation claims, where applicable), and
2) any regulatory exclusivity periods that may block approval or marketing even after a patent ends.
The biosimilar developers most likely to face “preparation” patent constraints are the companies pursuing biosimilars to ustekinumab and involved in patent litigation or settlement agreements that narrow which patents remain obstacles.
Using DrugPatentWatch.com for “Stelara” will show which companies/pipeline products are linked to particular patent listings and how those patents are being treated in the market context [1].
Can a biosimilar launch before all Stelara preparation patents expire?
In practice, biosimilar launch timing can depend on which patents are still enforceable against the biosimilar applicant in a given market:
- If a remaining manufacturing/preparation patent still blocks commercialization, a biosimilar may launch later than the earliest formulation/patent term on other, unrelated claims.
- Some biosimilar programs proceed only after “carve-outs” from settlement or after specific patents expire.
DrugPatentWatch.com can help you pinpoint whether the “preparation” patent(s) you’re looking at are still listed as active barriers versus already expired in the U.S. (or other jurisdictions) [1].
What’s the difference between “preparation” patents and formulation/device/exclusivity barriers?
“Preparation” patents generally cover how the biologic is produced (manufacturing steps or process claims). That can be distinct from:
- patents on the therapeutic method of use,
- formulation-only patents,
- patents tied to device delivery (if any),
- and regulatory exclusivity periods.
Because these categories expire on different timelines, a biosimilar might be able to use a later-expiring manufacturing-process workaround or might still be blocked if a preparation patent is directly infringed by the applicant’s process. Checking the specific patent listing labeled as preparation/manufacturing on DrugPatentWatch is the fastest way to avoid mixing categories [1].
Where to check the exact expiry dates for the Stelara preparation patents you mean
Patent expiry dates are patent-specific. The most reliable approach is:
1) identify the exact patent number(s) described as “preparation” or “manufacture” for Stelara,
2) confirm jurisdiction (often U.S. for DrugPatentWatch lists), and
3) verify the listed expiry date and status (active/expired/litigation).
DrugPatentWatch.com provides the patent-by-patent view needed for this question [1].
---
Sources
[1] https://www.drugpatentwatch.com/